Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model

Cardiovascular Research

Volumn 92, Issue 2, 2011, Pages 218-225

  Bikou, Olympia ^a   Thomas, Dierk ^a   Trappe, Kerstin ^a   Lugenbiel, Patrick ^a   Kelemen, Kamilla ^a   Koch, Martin ^a   Soucek, Radim ^a   Voss, Frederik ^a   Becker, Rdiger ^a   Katus, Hugo A ^a   Bauer, Alexander ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Atrial fibrillation; Connexin 43; Electrical remodelling; Gene therapy; Rhythm control

Indexed keywords

ADENOVIRUS VECTOR; CONNEXIN 43;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR GENE THERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ELECTROPORATION; EXPERIMENTAL PIG; HEART ATRIUM FIBRILLATION; HEART ATRIUM GENE TRANSFER; HEART LEFT VENTRICLE ENDDIASTOLIC DIAMETER; HEART LEFT VENTRICLE ENDSYSTOLIC DIAMETER; HEART RATE; HEART VENTRICLE SIZE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SINUS RHYTHM; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CONNEXIN 43; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; ELECTROPORATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART ATRIA; HEART RATE; SUS SCROFA; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 80054116111     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr209     Document Type: Article

References (38)

1. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010;375:1212-1223.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983;106:389-396. (Pubitemid 13028244)
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-484.
4. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D-8D. (Pubitemid 36369329)
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98: 946-952. (Pubitemid 28446646)
6. Hohnloser SH, Li YG. Drug treatment of atrial fibrillation: what have we learneDi Curr Opin Cardiol 1997;12:24-32. (Pubitemid 27116914)
7. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-666. (Pubitemid 28402090)
8. Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S et al. Preexistent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 2005;45:285-292. (Pubitemid 40094739)
9. Wright M, Haïssaguerre M, Knecht S, Matsuo S, O'Neill MD, Nault I et al. State of the art: catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:583-592. (Pubitemid 351843402)
10. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303: 333-340.
11. Verma A. Atrial-fibrillation ablation should be considered first-line therapy for some patients. Curr Opin Cardiol 2008;23:1-8. (Pubitemid 351339789)
12. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226. (Pubitemid 34059528)
13. Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010;16: 470-474.
14. Levin M. Isolation and community: a review of the role of gap-junctional communication in embryonic patterning. J Membr Biol 2002;185:177-192. (Pubitemid 34127605)
15. Spach MS, Heidlage JF. The stochastic nature of cardiac propagation at a microscopic level. Electrical description of myocardial architecture and its application to conduction. Circ Res 1995;76:366-380.
16. Lin X, Gemel J, Glass A, Zemlin CW, Beyer EC, Veenstra RD. Connexin40 and connexin43 determine gating properties of atrial gap junction channels. J Mol Cell Cardiol 2010;48:238-245.
17. Vozzi C, Dupont E, Coppen SR, Yeh HI, Severs NJ. Chamber-related differences in connexin expression in the human heart. J Mol Cell Cardiol 1999;31:991-1003. (Pubitemid 29241535)
18. Firouzi M, Ramanna H, Kok B, Jongsma HJ, Koeleman BP, Doevendans PA et al. Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res 2004;95:e29-e33.
19. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006;354: 2677-2688.
20. Thibodeau IL, Xu J, Li Q, Liu G, Lam K, Veinot JP et al. Paradigm of genetic mosaicism and lone atrial fibrillation: physiological characterization of a connexin 43-deletion mutant identified from atrial tissue. Circulation 2010;122:236-244.
21. Chaldoupi SM, Loh P, Hauer RN, de Bakker JM, van Rijen HV. The role of connexin40 in atrial fibrillation. Cardiovasc Res 2009;84:15-23.
22. Hauer RN, Groenewegen WA, Firouzi M, Ramanna H, Jongsma HJ. Cx40 polymorphism in human atrial fibrillation. Adv Cardiol 2006;42:284-291. (Pubitemid 43805871)
23. Wirka RC, Gore S, Van Wagoner DR, Arking DE, Lubitz SA, Lunetta KL et al. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:87-93.
24. Duffy HS, Wit AL. Is there a role for remodeled connexins in AF? No simple answers. J Mol Cell Cardiol 2008;44:4-13.
25. Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007; 87:425-456. (Pubitemid 47084677)
26. Liu X, Shi H, Tan H, Wang X, Zhou L, Gu J. Decreased connexin 43 and increased fibrosis in atrial regions susceptible to complex fractionated atrial electrograms. Cardiology 2009;114:22-29.
27. Bauer A, McDonald AD, Donahue JK. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 2004;61: 764-770. (Pubitemid 38249475)
28. Bauer A, McDonald AD, Nasir K, Peller L, Rade JJ, Miller JM et al. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation 2004;110:3115-3120. (Pubitemid 39492007)
29. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003;177:437-447. (Pubitemid 36411581)
30. Bauer A, Schnabel PA, Schreiner KD, Becker R, Voss F, Kraft P et al. Effects of propafenone on anisotropic conduction properties within the three-dimensional structure of the canine ventricular wall. Basic Res Cardiol 2001;96:175-183. (Pubitemid 32236787)
31. Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation 2005;111: 264-270. (Pubitemid 40165331)
32. Lamping KG, Rios CD, Chun JA, Ooboshi H, Davidson BL, Heistad DD. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol 1997;272: H310-H317.
33. Kass-Eisler A, Falck-Pedersen E, Alvira M, Rivera J, Buttrick PM, Wittenberg BA et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA 1993;90:11498-11502. (Pubitemid 24008666)
34. Trollet C, Bloquel C, Scherman D, Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther 2006;6:561-578. (Pubitemid 44524460)
35. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73.
36. Jansen JA, van Veen TAB, de Bakker JMT, van Rijen HVM. Cardiac connexins and impulse propagation. J Mol Cell Cardiol 2010;48:76-82.
37. Stergiopoulos K, Alvarado JL, Mastroianni M, Ek-Vitorin JF, Taffet SM, Delmar M. Hetero-domain interactions as a mechanism for the regulation of connexin channels. Circ Res 1999;84:1144-1155. (Pubitemid 29244776)
38. Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation 2010;121: 2263-2270.